default author photo

Alex Zhavoronkov

Insilico Medicine Shanghai Ltd.

SCHOLARLY PAPERS

6

DOWNLOADS

735

TOTAL CITATIONS

0

Scholarly Papers (6)

1.

Delphi-derived Framework for Healthspan-Oriented Care: The Cardiometabolic Health Perspective

Number of pages: 57 Posted: 30 Jan 2026
Medical University of Warsaw, Independent, Medical University of Warsaw, Independent, Independent, University of St. Gallen, Paul Stradins Clinical University Hospital Research Institute, Riga Technical University Institute of Smart Computer Technologies, Bar-Ilan University, Independent, Sheba Medical Center, University of Copenhagen - Center for Healthy Aging, Insilico Medicine Shanghai Ltd., Harvard Medical School - Genetics Division, Altos Labs, Université de Toulouse - WHO Collaborating Center for Frailty, Clinical and Geroscience Research, and Geriatric Training, University of Connecticut, Independent, Shanghai University of Medicine and Health Sciences and Independent
Downloads 223 (343,660)

Abstract:

Loading...

healthspan-oriented care, cardiometabolic diseases, intrinsic capacity, delphi-derived consensus, geroscience, aging

2.

Discovery of Novel MAT2A Inhibitors by an Allosteric Site-Compatible Fragment Growing Approach

Number of pages: 18 Posted: 10 Jan 2024
Insilico Medicine Shanghai Ltd., Insilico Medicine Shanghai Ltd., Insilico Medicine Shanghai Ltd., Insilico Medicine Shanghai Ltd., Insilico Medicine Shanghai Ltd., Insilico Medicine Shanghai Ltd., Insilico Medicine Shanghai Ltd., Insilico Medicine Shanghai Ltd., Insilico Medicine Shanghai Ltd., Insilico Medicine AI Limited, Insilico Medicine Shanghai Ltd., Insilico Medicine Shanghai Ltd. and Insilico Medicine Shanghai Ltd.
Downloads 131 (558,171)

Abstract:

Loading...

MAT2A Inhibitor, MTAP-deficient Tumor, Fragment Growing

3.

Higher Blood Biochemistry-Based Biological Age Developed by Advanced Deep Learning Techniques is Associated with Frailty in Geriatric Rehabilitation Inpatients: Resort

Number of pages: 25 Posted: 04 Jan 2024
University of Melbourne, University of Melbourne, Deep Longevity Limited, Insilico Medicine Shanghai Ltd. and VU University Amsterdam
Downloads 112 (630,858)

Abstract:

Loading...

Ageing, frailty, deep learning, laboratories, rehabilitation

4.

Synthesis and Structure-Activity Optimization of Azepane-Containing Derivatives as PTPN2/PTPN1 Inhibitors

Number of pages: 20 Posted: 19 Mar 2024
Insilico Medicine Shanghai Ltd., Insilico Medicine Shanghai Ltd., Insilico Medicine Shanghai Ltd., Insilico Medicine Shanghai Ltd., Insilico Medicine Shanghai Ltd., Insilico Medicine Shanghai Ltd., Insilico Medicine Shanghai Ltd., Insilico Medicine Shanghai Ltd., Insilico Medicine Shanghai Ltd., Insilico Medicine AI Limited, Insilico Medicine Shanghai Ltd., Insilico Medicine Shanghai Ltd. and Insilico Medicine Shanghai Ltd.
Downloads 111 (635,507)

Abstract:

Loading...

5.

Discovery of Novel and Selective SIK2 Inhibitors by the Application of Alphafold Structures and Generative Models

Number of pages: 26 Posted: 26 Jun 2023
Insilico Medicine Shanghai Ltd., Insilico Medicine Shanghai Ltd., Insilico Medicine Shanghai Ltd., Insilico Medicine Shanghai Ltd., Insilico Medicine Shanghai Ltd., Insilico Medicine Shanghai Ltd., Insilico Medicine Shanghai Ltd., Insilico Medicine AI Limited, Insilico Medicine Shanghai Ltd., Insilico Medicine Shanghai Ltd. and Insilico Medicine Shanghai Ltd.
Downloads 99 (704,534)

Abstract:

Loading...

Salt-inducible kinase 2, AlphaFold, Generative Models, Novel Selectivity

6.

Discovery of Pyrrolopyrimidinone Derivatives as Potent Pkmyt1 Inhibitors for the Treatment of Cancer

Number of pages: 12 Posted: 01 Oct 2024
affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Insilico Medicine Shanghai Ltd., affiliation not provided to SSRN, Insilico Medicine Shanghai Ltd., Insilico Medicine Shanghai Ltd., Insilico Medicine AI Limited, Insilico Medicine Shanghai Ltd., Insilico Medicine Shanghai Ltd. and Insilico Medicine Shanghai Ltd.
Downloads 59 (970,490)

Abstract:

Loading...

PKMYT1 inhibitor, Pyrrolopyrimidinone, Metabolic stability, Molecular docking